Our results demonstrated that the S1PR2 antagonist (JTE-013) almost completely blocked endothelial dysfunction and associated fission and dysfunction of mitochondria under HG conditions along with down-regulated HG-promoted expression of RhoA/ROCK1. The gene discussed is S1PR2; the disease is endothelial dysfunction.